VIEW ON PRLOG

SUZHOU, China – May 15, 2019 (PRLOG) – Re-Stem Biotech (Re-Stem or the Company), a biotechnology firm engaged in the research and development of cell-based therapies and products for various indications, including osteoarthritis, spinal cord injury and cancer, today announced a Grand Opening ceremony to mark the relocation and expansion of its corporate office and main research and development facility in Suzhou, China on May 18, 2019. The state-of-the-art facility will provide more GMP space and administrative space for the company’s growing needs. The event, which includes a tour of the new facilities, will be attended by municipal officials, technology and clinical partners, as well as local media.

Event Details

Date: Saturday, May 18, 2019

Time: 10:30 am – 12:00 pm

Location: 1463 Wuzhong Avenue, Building A1, Suzhou, Jiangsu Province, China

To register to attend this event, or for media enquiries, please contact judyanna.chen@restembiotech.com.

About Re-Stem Biotech Re-Stem Biotech (Re-Stem) is a biotechnology firm engaged in the research and development of cell-based therapies and products. Backed by state of the art GMP facilities and an international team of world-leading scientists, doctors and management team, Re-Stem currently has a robust technology platform including three profitable therapies on the market and eight other therapies and products in the pipeline. Incorporated and headquartered in 2012 in Suzhou, China, Re-Stem is focused on the large and aging population of China. It also operates clinics and research and development laboratories in Shenzhen, Beijing and Ganzhou.

Forward-Looking Statements Statements in this press release relating to plans, strategies, trends, specific activities or investments, and other statements that are not descriptions of historical facts and may be forward-looking statements are inherently subject to risks and uncertainties, and actual results could differ materially from those currently anticipated due to a number of factors, which include those regarding our ability to implement objective, plans and strategies for future operations. Forward-looking information may be identified by terms such as “will,” “may,” “expects,” “plans,” “intends,” “estimates,” “potential,” or “continue,” or similar terms or the negative of these terms. Although Re-Stem believes the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee that future results, performance or achievements will be obtained. Re-Stem does not have any obligation to update these forward-looking statements other than as required by law.

Contact: Judyanna Chen

Re-Stem Biotech

judyanna.chen@restembiotech.com